Scarica l'app Stockscreener
3.25
3.56%
-0.12
Precedente Chiudi:
$3.37
Aprire:
$3.37
Volume 24 ore:
410.56K
Relative Volume:
0.72
Capitalizzazione di mercato:
$207.03M
Reddito:
$157.08M
Utile/perdita netta:
$-70.36M
Rapporto P/E:
-2.9237
EPS:
-1.1116
Flusso di cassa netto:
$-71.69M
1 W Prestazione:
-13.10%
1M Prestazione:
-20.34%
6M Prestazione:
-4.69%
1 anno Prestazione:
+92.31%
Intervallo 1D:
$3.235
$3.45
Intervallo di 1 settimana:
$3.19
$3.76
Portata 52W:
$1.29
$5.08
Macrogenics Inc Stock (MGNX) Company Profile
Nome
Macrogenics Inc
Settore
Industria
Telefono
301-251-5172
Indirizzo
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
3.25 | 207.03M | 157.08M | -70.36M | -71.69M | -1.1116 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2024-11-07 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-31 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-05-10 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Downgrade | Stifel | Buy → Hold |
| 2024-05-10 | Downgrade | TD Cowen | Buy → Hold |
| 2024-04-26 | Iniziato | B. Riley Securities | Buy |
| 2024-04-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-03-04 | Reiterato | BTIG Research | Buy |
| 2024-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-22 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-11-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-02-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-04 | Iniziato | SMBC Nikko | Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-12 | Aggiornamento | Barclays | Underweight → Overweight |
| 2020-12-22 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-03 | Downgrade | Citigroup | Buy → Neutral |
| 2020-06-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2019-12-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Guggenheim | Neutral |
| 2019-02-07 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-02-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-02-06 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Downgrade | Citigroup | Neutral → Sell |
| 2018-12-10 | Downgrade | Raymond James | Outperform → Underperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-05-31 | Iniziato | Evercore ISI | Outperform |
| 2018-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-31 | Iniziato | Raymond James | Outperform |
Mostra tutto
Macrogenics Inc Borsa (MGNX) Ultime notizie
MacroGenics stock has October 23 data ahead in 2026 - ad-hoc-news.de
MacroGenics doses first patient in MGC030 cancer trial By Investing.com - Investing.com India
A patient has received the first dose of a new cancer treatment. - Stock Titan
Form 4 MacroGenics Inc For: 10 October By Investing.com - Investing.com Nigeria
Form 4 MacroGenics Inc For: 10 October By Investing.com - Investing.com UK
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? - Zacks Investment Research
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
MacroGenics insider exercises 8,000 options for MacroGenics stock - AD HOC NEWS
MacroGenics stock fell 2.47 percent on October 7 with pipeline data ahead - AD HOC NEWS
Ezio Bonvini Executes 8,000 MacroGenics Stock Options at $2.60 Each - Kalkine Media
At $2.60 a share, MacroGenics (MGNX) research chief exercises options for 8,000 shares. - Stock Titan
MacroGenics stock faces October data after a Q2 revenue miss - AD HOC NEWS
MacroGenics reports revenue miss and gets USD 6.33 target for MacroGenics stock - AD HOC NEWS
MacroGenics reports revenue miss and gets USD 6.33 target for MacroGenics stock - AD HOC NEWS
Current ratio of MacroGenics, Inc. – HAN:M55 - tradingview.com
MacroGenics, Inc. Revenue Breakdown – HAN:M55 - tradingview.com
Form 144 MACROGENICS INC. For: 27 September By Investing.com - Investing.com Australia
Form 144 MACROGENICS INC. For: 27 September By Investing.com - Investing.com Nigeria
Form 144 MACROGENICS INC. For: 27 September By Investing.com - Investing.com UK
MacroGenics stock falls 3.95 percent as pipeline expands - AD HOC NEWS
MacroGenics stock holds at USD 4.12 as cash strength stands out - AD HOC NEWS
Former MacroGenics (NASDAQ: MGNX) officer lines up another stock sale - stocktitan.net
MacroGenics stock edges lower as biotech analysts highlight risk and upside - AD HOC NEWS
MacroGenics2026 Funding Rounds & List of Investors - tracxn.com
MacroGenics (NASDAQ:MGNX): A Minervini Trend Template High-Growth Momentum Case Study - ChartMill
MGNX: Transformed structure, strong cash, and advancing antibody pipeline with key clinical milestones ahead - TradingView
MacroGenics at H.C. Wainwright conference: leaner model, rich pipeline - Investing.com
MGNX Stock Hits 16-Month High, But This Analyst Sees Another 140% Potential Upside - Stocktwits
MacroGenics CEO Eric Risser to present at H.C. Wainwright Global Investment Conference - Bitget
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead (NASDAQ:MGNX) - Seeking Alpha
MacroGenics (MGNX) Institutional Ownership 2026 - marketbeat.com
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Macrogenics Inc (MGNX) Senior VP, GC, and Secretary Jeffrey Pete - GuruFocus
Macrogenics senior VP sells $129,085 in shares By Investing.com - Investing.com Australia
Macrogenics senior VP sells $129,085 in shares By Investing.com - Investing.com Nigeria
Macrogenics senior VP sells $129,085 in shares By Investing.com - Investing.com Canada
Macrogenics senior VP sells $129,085 in shares By Investing.com - Investing.com South Africa
Macrogenics senior VP sells $129,085 in shares By Investing.com - Investing.com India
Macrogenics senior VP sells $129,085 in shares - Investing.com
MacroGenics (MGNX) counsel sells 31K shares, now holds none - Stock Titan
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
MacroGenics (NASDAQ: MGNX) officer prepares stock sales under Rule 144 - Stock Titan
MacroGenics (MGNX) Q1 2026 Results: The Bottom-Line Figure Beats Its Comparison in the Latest Session - vinanet.vn
MacroGenics (MGNX) exec adds 40K shares via option exercise - stocktitan.net
MacroGenics (NASDAQ: MGNX) insider lines up new stock sale after recent trade - stocktitan.net
MGNX Maintained by B. Riley Securities -- Price Target Raised to $11.00 - GuruFocus
B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating - marketscreener.com
MacroGenics (MGNX) Stock Faces A Revenue Reality Check After Deeper Losses - Sahm
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst? - Yahoo Finance
Macrogenics Inc Azioni (MGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Macrogenics Inc Azioni (MGNX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Thomas Spitznagel | Former Officer |
Sep 21 '26 |
Proposed Sale |
4.14 |
15,811 |
65,530 |
0 |
| Peters Jeffrey Stuart | Senior VP, GC, and Secretary |
Aug 19 '26 |
Sale |
4.15 |
31,105 |
129,086 |
0 |
| Jeffrey Peters | Officer |
Aug 19 '26 |
Proposed Sale |
4.15 |
31,105 |
129,145 |
0 |
| Jay Siegel | Former Director |
Aug 17 '26 |
Proposed Sale |
4.18 |
42,080 |
175,695 |
0 |
| Bonvini Ezio | Sr VP, Research & CSO |
Aug 17 '26 |
Option Exercise |
2.60 |
40,000 |
104,000 |
185,799 |
| Jay Siegel | Former Director |
Aug 03 '26 |
Proposed Sale |
3.75 |
34,916 |
130,935 |
0 |
| Thomas Spitznagel | Former Officer |
Jul 13 '26 |
Proposed Sale |
4.44 |
17,000 |
75,529 |
0 |
| Koenig Scott | Director |
Feb 15 '26 |
Option Exercise |
0.00 |
21,165 |
0 |
867,240 |
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):